Monte Rosa said it entered a clinical supply agreement with Johnson & Johnson to support a planned Phase 2 trial of MRT-2359 in combination with apalutamide (ERLEADA) for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The company expects the study to start in Q3 2026 and enroll up to 25 patients. Endpoints include PSA response, RECIST response, duration of response, progression-free survival, radiographic progression-free survival, and safety. Monte Rosa will sponsor and conduct the trial, while Johnson & Johnson will supply ERLEADA. Results from an ongoing Phase 1/2 study of MRT-2359 plus enzalutamide were previously presented at the 2026 ASCO GU Cancers Symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672321) on March 16, 2026, and is solely responsible for the information contained therein.